417 related articles for article (PubMed ID: 27306171)
1. Can you teach old drugs new tricks?
Nosengo N
Nature; 2016 Jun; 534(7607):314-6. PubMed ID: 27306171
[No Abstract] [Full Text] [Related]
2. Repurposing Drugs in Oncology: Next Steps.
Verbaanderd C; Meheus L; Huys I; Pantziarka P
Trends Cancer; 2017 Aug; 3(8):543-546. PubMed ID: 28780930
[TBL] [Abstract][Full Text] [Related]
3. Drug rediscovery to prevent off-label prescription reduces health care costs: the case of tioguanine in the Netherlands.
Mulder CJ; van Asseldonk DP; de Boer NK
J Gastrointestin Liver Dis; 2014 Jun; 23(2):123-5. PubMed ID: 24949602
[No Abstract] [Full Text] [Related]
4. GW-1000. GW Pharmaceuticals.
Smith PF
Curr Opin Investig Drugs; 2004 Jul; 5(7):748-54. PubMed ID: 15298072
[TBL] [Abstract][Full Text] [Related]
5. The right combination.
Nature; 2006 Jan; 439(7075):390-1. PubMed ID: 16437083
[No Abstract] [Full Text] [Related]
6. The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis?
Giovannoni G; Baker D; Schmierer K
Mult Scler Relat Disord; 2015 Jan; 4(1):3-5. PubMed ID: 25787047
[TBL] [Abstract][Full Text] [Related]
7. SuperGenerics: a better alternative for biogenerics.
Charles SA
Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591
[No Abstract] [Full Text] [Related]
8. Repurposing Clinical Molecule Ebselen to Combat Drug Resistant Pathogens.
Thangamani S; Younis W; Seleem MN
PLoS One; 2015; 10(7):e0133877. PubMed ID: 26222252
[TBL] [Abstract][Full Text] [Related]
9. Scientific advice - is drug repurposing missing a trick?
Pantziarka P
Nat Rev Clin Oncol; 2017 Aug; 14(8):455-456. PubMed ID: 28534529
[No Abstract] [Full Text] [Related]
10. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
Dinh TQ
Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
[No Abstract] [Full Text] [Related]
11. New Therapeutic Uses for Existing Drugs.
Austin BA; Gadhia AD
Adv Exp Med Biol; 2017; 1031():233-247. PubMed ID: 29214576
[TBL] [Abstract][Full Text] [Related]
12. The scope and requirements related to preclinical and clinical studies of a new medicinal product, including biotechnological and biosimilar products.
Brodniewicz-Proba T
Acta Pol Pharm; 2008; 65(6):641-5. PubMed ID: 19172845
[TBL] [Abstract][Full Text] [Related]
13. Break with tradition.
Jayaraman KS
Nature; 2006 Jul; 442(7101):342-3. PubMed ID: 16871181
[No Abstract] [Full Text] [Related]
14. The ongoing regulation of generic drugs.
Frank RG
N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
[No Abstract] [Full Text] [Related]
15. Biotech industry struggles with generics approval.
Knight J
Nature; 2004 Jun; 429(6992):588. PubMed ID: 15190316
[No Abstract] [Full Text] [Related]
16. FDA notifications. Tentative approval for generic lamivudine/zidovudine.
AIDS Alert; 2007 Oct; 22(10):119-20. PubMed ID: 18416011
[No Abstract] [Full Text] [Related]
17. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
McCabe AR
Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
[No Abstract] [Full Text] [Related]
18. The FDA's generic-drug approval process: similarities to and differences from brand-name drugs.
Kefalas CH; Ciociola AA
Am J Gastroenterol; 2011 Jun; 106(6):1018-21. PubMed ID: 21637264
[No Abstract] [Full Text] [Related]
19. Using a drug-safety tool to prevent competition.
Sarpatwari A; Avorn J; Kesselheim AS
N Engl J Med; 2014 Apr; 370(16):1476-8. PubMed ID: 24738666
[No Abstract] [Full Text] [Related]
20. A brief history of generic substitution in the USA.
Sullivan CG
Pharm Pat Anal; 2012 Mar; 1(1):9-11. PubMed ID: 24236706
[No Abstract] [Full Text] [Related]
[Next] [New Search]
